Form 4: Aldeyra Therapeutics Director Reports Changes in Beneficial Ownership

Nancy Miller-Rich, a director of Aldeyra Therapeutics, reported transactions involving the company's common stock due to trades executed by an investment advisor.

Summary

• Nancy Miller-Rich, a director of Aldeyra Therapeutics, filed a Form 4 detailing changes in her beneficial ownership of the company's common stock.
• The reported transactions include the purchase and disposal of common stock on May 3, 2021, and April 12, 2023.
• On May 3, 2021, 413 shares were acquired at $12.81 per share and then disposed of.
• On April 12, 2023, 509 shares were acquired at $10.13 per share, resulting in a total of 922 shares disposed of.
• The transactions were executed by an investment advisor in a managed account without the director's prior knowledge or instruction.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing, so the sentiment is neutral. It simply reports transactions without indicating a positive or negative outlook.

Management Comments

• The purchases reported herein were executed under the trading discretion of an investment advisor in a managed account, without any instruction from or knowledge of the Reporting Person.
• The Reporting Person only recently become aware of these transactions.

Industry Context

Form 4 filings are a routine part of regulatory compliance for corporate insiders, providing transparency into their trading activities. These filings are closely watched by investors seeking insights into management's perspective on the company's prospects.

Stakeholder Impact

• The filing provides transparency to shareholders regarding the trading activities of a company director.

Key Dates